Financial Performance - Enovis reported first-quarter 2025 net sales of $559 million, an 8% increase on a reported basis and 9% on a comparable basis year-over-year[3]. - The net loss from continuing operations for the first quarter was $56 million, representing a loss margin of 10.0%[4]. - Adjusted EBITDA for the first quarter was $99 million, equating to 17.7% of sales, an increase of 160 basis points compared to the prior year[4]. - Reconstructive sales grew 11% year-over-year on a reported basis, while P&R sales increased by 5%[3]. - Enovis Corporation reported a net loss from continuing operations of $55.6 million for the three months ended April 4, 2025, compared to a loss of $71.8 million for the same period in 2024, representing a 22.5% improvement[26]. - Adjusted EBITDA for the same period was $99.2 million, with an adjusted EBITDA margin of 17.7%, up from $83.2 million and 16.1% in the prior year, indicating a 19.5% increase in adjusted EBITDA[26]. - Net sales increased to $558.8 million, a growth of 8.2% from $516.3 million in the previous year, driven by strong performance in both the Prevention & Recovery and Reconstructive segments[33]. Revenue Outlook - Enovis updated its 2025 revenue outlook to a range of $2.22-2.25 billion, up from previous expectations of $2.19-2.22 billion[7]. - Adjusted EBITDA for 2025 is forecasted to be $385-395 million, revised down from $405-415 million due to a $20 million tariff-related impact[7]. - Full-year adjusted earnings per share guidance was updated from $3.10-$3.25 to $2.95-$3.10[7]. Leadership Changes - The company appointed Damien McDonald as CEO, effective May 12, 2025[6]. Strategic Focus - Enovis emphasized a focus on disciplined execution and strategic investment to drive above-market growth[5]. - The company is committed to a multi-year cadence of high-impact product launches across its portfolio[5]. Asset and Liability Management - Total current assets rose to $1,218.2 million as of April 4, 2025, compared to $1,146.4 million at the end of 2024, reflecting a 6.3% increase[30]. - Enovis Corporation's total liabilities increased to $2,254.8 million as of April 4, 2025, from $2,154.4 million at the end of 2024, representing a 4.6% rise[30]. - Cash and cash equivalents decreased to $38.5 million from $48.2 million at the end of 2024, marking a decline of 19.5%[31]. Operational Efficiency - The company reported a net cash used in operating activities of $1.6 million for the three months ended April 4, 2025, a significant improvement from $36.2 million used in the same period last year[32]. - The gross profit margin (GAAP) improved to 59.4% for the three months ended April 4, 2025, compared to 57.7% in the prior year[28]. - The company completed strategic purchases of economic interest on future royalty payments for a total of $43.8 million, with a recognized charge of $35.8 million for the net present value of these purchases[26].

Financial Performance - Enovis reported first-quarter net sales of $559 million, reflecting an 8% increase on a reported basis and a 9% increase on a comparable basis year-over-year [2] - The Reconstructive segment saw net sales growth of 11% on both a reported and comparable basis, while the Prevention & Recovery segment grew by 5% on a reported basis and 7% on a comparable basis [2] - The company experienced a net loss from continuing operations of $56 million, equating to a loss of 10.0% of sales, with adjusted EBITDA of $99 million, representing a margin of 17.7% [3] Management Commentary - The CEO of Enovis stated that the company had a strong start to 2025, with revenues and margins exceeding expectations, attributing this performance to the strength of their business system and disciplined execution [4] Financial Outlook - Enovis updated its 2025 revenue expectations to a range of $2.22-2.25 billion, up from previous expectations of $2.19-2.22 billion, while adjusted EBITDA is now forecasted to be $385-395 million, down from $405-415 million due to tariff impacts [5] Product Segments - The first-quarter sales growth in the Prevention & Recovery segment was 5.2%, while the Reconstructive segment achieved a growth rate of 11.3% [39] - The U.S. Reconstructive sales grew by 11.4%, and international Reconstructive sales increased by 11.1% [39] Non-GAAP Financial Measures - Adjusted net income from continuing operations for the first quarter was reported at $46.5 million, with an adjusted net income margin of 8.3% [21] - The adjusted EBITDA margin increased by 160 basis points compared to the prior year, indicating improved operational efficiency [3][20]

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on May 8, 2025, at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning [1]. Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and those participating in the call can dial (833) 335-0887 using Access Code: 482081 [2]. - A replay of the call will be available on the Enovis website later that day [2]. Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [3]. - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3]. - Enovis shares are listed on the New York Stock Exchange under the symbol ENOV [3]. Group 3: Availability of Information - Enovis routinely announces material information to investors through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4]. - The company encourages investors and the media to review the information shared on its Investor Relations website [4].

Core Points - Enovis Corporation announced the appointment of Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola who will retire [1][3] - The company expects first quarter revenues to be between $555 million and $563 million, with adjusted EBITDA projected to be between $97 million and $100 million [1][6] Leadership Transition - Sharon Wienbar, Lead Independent Director, expressed enthusiasm for McDonald's appointment, highlighting his strong track record in the medical technology sector [2] - McDonald has over 35 years of experience in the medical device industry, previously serving as CEO of LivaNova, where he improved growth, profitability, and shareholder value [2][3] - Following Trerotola's retirement, Wienbar will assume the role of independent Chair of the Board [3] Company Overview - Enovis Corporation is focused on developing clinically differentiated medical technology solutions aimed at improving patient outcomes [4] - The company emphasizes a culture of continuous improvement and innovation, with a diverse range of products and services in orthopedics and beyond [4]

Core Insights - Enovis is showcasing its expanding portfolio of foot and ankle solutions at the ACFAS Annual Scientific Conference, emphasizing its commitment to education and innovative partnerships in the field [2][3]. Product Highlights - The company will feature the Tarsoplasty Percutaneous Lapidus Correction System, which offers a minimally invasive option for Lapidus bunionectomy, enhancing the patient's perioperative experience [3]. - Enovis will present new research on the Arsenal Foot™ Plating System, focusing on how screw angulation and plate design affect surgical outcomes [3]. Events and Engagements - Enovis is hosting two key events during the conference: "Phoenix Rising: Foot & Ankle Edition" on March 28 and a Flatfoot/MIS Techniques Workshop on March 26 [4]. - Attendees are encouraged to visit booth 1820 for hands-on engagement with Enovis products and to follow the company's social media for live updates [5]. Company Overview - Enovis Corporation is a medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [6].

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures related to the author's position and affiliations [1][2]. Summary by Sections - No relevant company or industry information is presented in the content provided, as it primarily consists of disclaimers and disclosures without any analytical content [1][2].

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $561 million, up 23% year-over-year and up 7% on a constant currency basis [18][22] - Adjusted gross margin for the fourth quarter was 60.1%, an increase of 150 basis points year-over-year [20] - Adjusted EBITDA grew 38%, delivering a margin of 20.1%, up 210 basis points compared to the same quarter last year [21] - Adjusted earnings per share were $0.98, a 24% increase versus the prior year [22][23] Business Line Data and Key Metrics Changes - In the Recon segment, global revenue grew 59% reported and 10% on a comparable basis, with double-digit growth in both Hip Knee and Extremities segments [10][19] - The P&R segment experienced 3% growth, reflecting a stable market environment [15][19] - The Lima acquisition significantly contributed to the growth and integration of the Recon business, exceeding revenue and profit goals [13][14] Market Data and Key Metrics Changes - U.S. Recon grew 7%, with 10% growth in U.S. Extremities and 8% in Hip Knees [10] - Internationally, the company achieved 13% growth while executing integration plans [11] - The company anticipates high single-digit growth in Recon for 2025, with stable low single-digit growth in P&R [26] Company Strategy and Development Direction - The company aims for continued growth through new product launches and cross-selling opportunities, particularly in the Recon segment [12][34] - The focus for 2025 will be on small bolt-on acquisitions while completing the integration of Lima [44][46] - The company is committed to maintaining a strong cash flow and reducing debt levels while pursuing strategic growth opportunities [72][74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategic goals and operational performance, despite a noncash goodwill impairment of $645 million [23][24] - The company expects 2025 to be another year of strong execution, with revenue guidance of $2.19 billion to $2.22 billion [26][28] - Management highlighted the importance of addressing tariff impacts and maintaining supply chain resilience [31][100] Other Important Information - The company is transitioning leadership as the CEO announced plans to retire later this year [36][39] - The integration of Lima is largely complete, with ongoing opportunities for cross-selling and operational improvements [88][92] Q&A Session Summary Question: What is the M&A strategy post-Lima? - The company plans to focus on small bolt-on acquisitions in 2025 while ensuring the successful integration of Lima [44][46] Question: Is there a pathway to double-digit growth in Recon? - Management believes there are multiple paths to achieve double-digit growth, but has set a strategic goal of high single digits for 2025 [49][51] Question: What are the margin assumptions for 2025? - The company expects adjusted EBITDA margin improvement of 60 to 70 basis points for 2025, driven by core operating leverage and synergies from Lima [58][61] Question: How is the integration of Lima progressing? - The integration is largely complete, with key channel integrations and leadership team combinations finalized, allowing for a focus on cross-selling opportunities [92][94] Question: What are the expectations for the Hip business in 2025? - The new Hip products are expected to launch in the first half of 2025, which should help recapture lost market share and drive growth [84][86] Question: How will the company address tariff impacts? - The company has been working on supply chain diversification and pricing strategies to mitigate the impact of tariffs [98][100]

Financial Data and Key Metrics Changes - In Q4 2024, Enovis reported sales of $561 million, representing a 23% increase year-over-year and a 7% increase on a constant currency basis [18][22] - Adjusted gross margin for Q4 was 60.1%, up 150 basis points year-over-year, driven by favorable segment mix including the addition of Lima [20] - Adjusted EBITDA grew 38% in Q4, delivering a margin of 20.1%, an increase of 210 basis points compared to the same quarter last year [21][25] - Adjusted earnings per share reached $0.98, a 24% increase from the prior year [22] Business Line Data and Key Metrics Changes - The Recon segment experienced 59% reported global revenue growth, with a 10% increase on a comparable basis in Q4 [10][19] - U.S. Recon grew 7%, with 10% growth in U.S. Extremities and 8% in Hip Knees [10] - The P&R segment saw stable growth of 3%, with EBITDA margins expanding by 130 basis points year-over-year [15][16] Market Data and Key Metrics Changes - International revenue in Recon grew by 13%, supported by successful integration plans and new product launches [11] - The company anticipates high single-digit growth in Recon for 2025, with stable low single-digit growth in P&R [26] Company Strategy and Development Direction - Enovis aims for continued growth through new product launches and cross-selling opportunities, particularly in the Recon segment [12][34] - The Lima acquisition has been pivotal in enhancing the Recon business, with successful integration and exceeding revenue and profit goals [13][14] - The company plans to focus on small bolt-on acquisitions in 2025 while continuing to integrate Lima and improve operational efficiencies [44][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategic goals and operational performance, despite a non-cash goodwill impairment of $645 million due to a decrease in share price [23][24] - The company expects 2025 to be another year of strong execution, with revenue guidance of $2.19 billion to $2.22 billion and adjusted EBITDA in the range of $405 million to $415 million [26][28] - Management highlighted the importance of navigating tariff impacts and maintaining supply chain resilience [31][33] Other Important Information - The company is preparing for a leadership transition as the CEO plans to retire later in the year, with an active search for a successor [36][39] - The company expects to achieve positive free cash flow in 2025 while continuing to invest in growth and integration efforts [72][74] Q&A Session Summary Question: M&A strategy post-Lima - Management indicated that 2025 will focus on small bolt-on acquisitions while completing the Lima integration and starting to deleverage the company [44][46] Question: Pathway to double-digit growth in Recon - Management believes there are multiple paths to achieve double-digit growth in Recon, but has set a strategic goal of high single digits for 2025 [49][51] Question: Q1 phasing and contribution - The company expects 2 to 3 extra selling days in Q1, contributing to a strong start, with momentum building in the business [54][56] Question: Margin guidance for 2025 - Management expects 60 to 70 basis points of margin improvement in 2025, driven by core operating leverage and synergies from the Lima acquisition [58][60] Question: U.S. vs. OUS market dynamics - Management noted strong demand outside the U.S. and a gradual improvement in the U.S. market, with expectations for continued share gains across all anatomies [64][70] Question: Free cash flow and debt outlook - The company anticipates positive free cash flow in 2025, with a goal to reduce leverage from 3.5x to the low 3s by year-end [72][74] Question: Pricing assumptions for 2025 - Management expects a return to some downward price pressure in the Recon segment, while P&R is anticipated to remain flat [76][80] Question: Lima integration status - The integration is largely complete, with key channel integrations and product roadmaps finalized, now focusing on cross-selling and operational improvements [88][92] Question: Tariff mitigation strategies - The company is implementing multiple sourcing strategies and inventory management to mitigate tariff impacts, with a focus on long-term health [98][100]

Group 1 - Enovis reported quarterly earnings of $0.98 per share, exceeding the Zacks Consensus Estimate of $0.92 per share, and up from $0.79 per share a year ago, representing an earnings surprise of 6.52% [1] - The company posted revenues of $560.98 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.84%, and an increase from $455.02 million year-over-year [2] - Enovis has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Group 2 - The stock has underperformed the market, losing about 4.1% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.68 on revenues of $552.17 million, and for the current fiscal year, it is $3.19 on revenues of $2.23 billion [7] - The Zacks Industry Rank places Medical Info Systems in the bottom 49% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ENOVIS CORPORATION (Exact name of registrant as specified in its charter) S ...